These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 34474712

  • 1. Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis and other atopic comorbidities.
    Spergel JM, Blaiss MS, Lio P, Kessel A, Cantrell WC, Takiya L, Werth JL, O'Connell MA, Zang C, Cork MJ.
    Allergy Asthma Proc; 2021 Sep 01; 42(5):425-431. PubMed ID: 34474712
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
    Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS, Eichenfield LF, Forsha DW, Rees WC, Simpson EL, Spellman MC, Stein Gold LF, Zaenglein AL, Hughes MH, Zane LT, Hebert AA.
    J Am Acad Dermatol; 2016 Sep 01; 75(3):494-503.e6. PubMed ID: 27417017
    [Abstract] [Full Text] [Related]

  • 3. Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study.
    Eichenfield LF, Gower RG, Xu J, Alam MS, Su JC, Myers DE, Sanders P, Vlahos B, Zang C, Lan J, Werth J.
    Am J Clin Dermatol; 2023 Jul 01; 24(4):623-635. PubMed ID: 37184828
    [Abstract] [Full Text] [Related]

  • 4. Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years.
    Luger TA, Hebert AA, Zaenglein AL, Silverberg JI, Tan H, Ports WC, Zielinski MA.
    Paediatr Drugs; 2022 Mar 01; 24(2):175-183. PubMed ID: 35292919
    [Abstract] [Full Text] [Related]

  • 5. Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild-to-moderate atopic dermatitis.
    Eichenfield LF, Yosipovitch G, Stein Gold LF, Kalabis M, Zang C, Vlahos B, Sanders P, Myers DE, Bushmakin AG, Cappelleri JC, Olivadoti M, Paller AS.
    Pediatr Dermatol; 2020 Nov 01; 37(6):1030-1037. PubMed ID: 32981097
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A phase 2b, randomized, double-blind, multicenter, vehicle-controlled study to assess the efficacy and safety of two crisaborole regimens in Japanese patients aged 2 years and older with mild-to-moderate atopic dermatitis.
    Fujita K, Yagi M, Moriwaki S, Yoshida M, Graham D.
    J Dermatol; 2021 Nov 01; 48(11):1640-1651. PubMed ID: 34435694
    [Abstract] [Full Text] [Related]

  • 8. Maintenance of Investigator's Static Global Assessment Response with Once-Daily Crisaborole in Participants with Mild to Moderate Atopic Dermatitis.
    Eichenfield LF, Stein Gold LF, Lynde C, Guenther L, Greenberger S, Chu CY, Ghodsi Z, Vlahos B, Sanders P, Cha A, Canosa JM.
    Dermatol Ther (Heidelb); 2024 Apr 01; 14(4):875-892. PubMed ID: 38546803
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Magnitude of benefit for topical crisaborole in the treatment of atopic dermatitis in children and adults does not look promising: a critical appraisal.
    Ahmed A, Solman L, Williams HC.
    Br J Dermatol; 2018 Mar 01; 178(3):659-662. PubMed ID: 29205284
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of crisaborole ointment in Chinese and Japanese patients aged ≥2 years with mild-to-moderate atopic dermatitis.
    Ma L, Zhang L, Kobayashi M, Tao X, Qian Q, Cheng H, Liu S, Zhou Y, Chen Y, Zhang J.
    J Dermatol; 2023 Jul 01; 50(7):847-855. PubMed ID: 37154471
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups.
    Callender VD, Alexis AF, Stein Gold LF, Lebwohl MG, Paller AS, Desai SR, Tan H, Ports WC, Zielinski MA, Tallman AM.
    Am J Clin Dermatol; 2019 Oct 01; 20(5):711-723. PubMed ID: 31264114
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis.
    Geng B, Hebert AA, Takiya L, Miller L, Werth JL, Zang C, Sanders P, Lebwohl MG.
    Dermatol Ther (Heidelb); 2021 Oct 01; 11(5):1667-1678. PubMed ID: 34379285
    [Abstract] [Full Text] [Related]

  • 16. Examining the association between pruritus and quality of life in patients with atopic dermatitis treated with crisaborole.
    Ständer S, Yosipovitch G, Bushmakin AG, Cappelleri JC, Luger T, Tom WL, Ports WC, Zielinski MA, Tallman AM, Tan H, Gerber RA.
    J Eur Acad Dermatol Venereol; 2019 Sep 01; 33(9):1742-1746. PubMed ID: 31132182
    [Abstract] [Full Text] [Related]

  • 17. Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open-Label, Maximal-Use Systemic Exposure Study.
    Zane LT, Kircik L, Call R, Tschen E, Draelos ZD, Chanda S, Van Syoc M, Hebert AA.
    Pediatr Dermatol; 2016 Jul 01; 33(4):380-7. PubMed ID: 27193740
    [Abstract] [Full Text] [Related]

  • 18. Translating the Investigator's Static Global Assessment to the Eczema Area and Severity Index in Studies of Crisaborole for Atopic Dermatitis.
    Thyssen JP, Zang C, Neary MP, Bushmakin AG, Cappelleri JC, Cha A, Russo C, Luger TA.
    Dermatol Ther (Heidelb); 2021 Jun 01; 11(3):845-853. PubMed ID: 33728583
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and Safety of Crisaborole Ointment 2% in Chinese Patients Aged ≥ 2 Years with Mild to Moderate Atopic Dermatitis.
    Ma L, Tao X, Liu S, Cheng H, Fang R, Zhao Y, Cha A, Encinas GA, Zhou Y, Deng Y, Zhang J.
    Dermatol Ther (Heidelb); 2024 May 01; 14(5):1229-1243. PubMed ID: 38748345
    [Abstract] [Full Text] [Related]

  • 20. Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial.
    Bissonnette R, Pavel AB, Diaz A, Werth JL, Zang C, Vranic I, Purohit VS, Zielinski MA, Vlahos B, Estrada YD, Saint-Cyr Proulx E, Ports WC, Guttman-Yassky E.
    J Allergy Clin Immunol; 2019 Nov 01; 144(5):1274-1289. PubMed ID: 31419544
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.